-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EYHr851i8I1EA8Byi+vfbswa//ckysMIEdcnRJ3hn0LDhjrNu2pNaFdHVjOtTXha pzyuBTwAEWbIUgRnu6m41w== 0001048477-04-000049.txt : 20040519 0001048477-04-000049.hdr.sgml : 20040519 20040518203324 ACCESSION NUMBER: 0001048477-04-000049 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040518 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20040519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 04817298 BUSINESS ADDRESS: STREET 1: 371 BEL MARIN KEYS BLVD STREET 2: STE 210 CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4158846700 MAIL ADDRESS: STREET 1: 371 BEL MARIN KEYS BLVD STREET 2: STE 210 CITY: NOVATO STATE: CA ZIP: 94949 8-K 1 form8k_051804.htm Form 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 18, 2004

BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-26727

68-0397820

(State or other jurisdiction

of incorporation or organization)

(Commission File Number)

(IRS Employer

Identification No.)


371 Bel Marin Keys Boulevard, Suite 210, Novato, California		94949
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (415) 506-6700

Not Applicable

(Former name or former address, if changed since last report)

Item 5. Other Events.

On May 18, 2004, BioMarin Pharmaceutical Inc. (the “Registrant”), issued a press release regarding the closing of its previously announced transaction related to obtaining the Orapred pediatrics business from Medicis Pharmaceutical Corporation. The Registrant´s press release issued on May 18, 2004 is attached hereto as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.

(a)

Financial Statements of Business Acquired.

Not Applicable.

(b)

Pro Forma Financial Information.

Not Applicable.

(c)

Exhibits.


Exhibit 99.1		Press Release of the Registrant dated May 18, 2004.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		BioMarin Pharmaceutical Inc., a Delaware corporation


Date: May 18, 2004	By:	/s/ Louis Drapeau
		Louis Drapeau Chief Financial Officer

EXHIBIT INDEX


Exhibit No.		Description
Exhibit 99.1		Press Release of the Registrant dated May 18, 2004

EX-99 2 ex_99-1.htm

Exhibit 99.1


Contacts:

Joshua A. Grass		Susan Ferris
Sr. Manager, Investor and Financial Relations		Manager, Corporate Communications
BioMarin Pharmaceutical Inc.		BioMarin Pharmaceutical Inc.
(415) 506-6777		(415) 506-6701

For Immediate Release:

BioMarin Completes Ascent Pediatrics Transaction

Novato, CA, May 18, 2004 – BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced that it has completed the transaction, announced April 20, 2004, to obtain Ascent Pediatrics, a profitable pediatrics business that includes Orapred^®, the top selling drug in its class for treatment of asthma in children, and the national field force that currently calls upon pediatricians throughout the United States.

BioMarin develops innovative biopharmaceutical products and commercializes therapeutics for serious pediatric diseases.

BioMarin’s press releases and other company information are available online at http://www.BMRN.com. Information on BioMarin’s website is not incorporated by reference into this press release.

Orapred is a registered trademark of Ascent Pediatrics, Inc., a wholly owned subsidiary of Medicis Pharmaceutical Corporation.

_________________

-----END PRIVACY-ENHANCED MESSAGE-----